ORAL01.01: A Prospective, Multi-Institutional Assessment of Four Assays for PD-L1 Expression in NSCLC by Immunohistochemistry
ORAL01.02: Biopsies in Initial Diagnosis of Non–Small Cell Lung Cancer in US Community Oncology Practices: Implications for First-Line Immunotherapy
ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC
ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1–Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results
ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC
ORAL02.02: Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis
ORAL02.03: Robust Correlation Between Metabolic Response Measured with 18F-FDG PET Soon After Therapy and Clinical Outcome in Lung Cancer
ORAL02.04: Predictors of Adverse Perioperative Outcome Following Lobectomy: A Population Based Analysis
ORAL02.05: Understanding Internal Differences in N-Category-Stratified Non–Small Cell Lung Cancer (NSCLC) Survival
MINI01.01: Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3
MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC
MINI01.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC
MINI01.04: ROS1 Fusion Chinese Lung Adenocarcinoma Patients Treated with Crizotinib Detected Using Next-Generation Genotyping from ctDNA
MINI01.05: RALPB1 Mediate ALK Resistance in Non–Small Cell Lung Cancer
MINI01.06: Circulating Angiogenesis Biomarkers are Predictive for Early Stage Non–Small Cell Lung Cancer Progression and Clinical Outcome
MINI01.07: Predictors of Conversion to Thoracotomy in VATS Lobectomy Patients
MINI01.08: Disparities in the Management of Patients with Stage I Small Cell Lung Cancer (SCLC): A Surveillance, Epidemiology and End Results (SEER) Analysis
MINI01.09: Outcomes of Early Stage Large Cell Neuroendocrine Lung Carcinoma (LCNELC): A National Cancer Database (NCDB) Analysis
MINI01.10: Diverse Populations may be Underrepresented in Community Lung Cancer Screening Programs
MINI01.11: Radiotherapy Plus EGFR TKIs for Brain Metastasis in EGFR-Mutant Non–Small Cell Lung Cancer: A Retrospective Analysis of a Single Institution
MINI01.12: Angiogenesis Biomarkers are Associated with Progression Free Survival in Non–Small Cell Lung Cancer Treated with SBRT
MINI01.13: Prediction of Lung Toxicity in the Definitive Radiotherapy of Non–Small Cell Lung Cancer using Clinical, Dosimetric and Biologic Factors
MINI01.14: Self-Efficacy and Decisions in Lung Cancer: Early Stage Lung Cancer Comparative Effectiveness Research Consortium Results
MINI01.15: Prophylactic Cranial Irradiation (PCI) for Limited Small Cell Lung Cancer (LSCLC): An IASLC Physician Survey
MINI01.16: Not So Easy: Readability Assessment of Patient Education Material on Non–Small Cell Lung Cancer Immunotherapy
MINI01.17: Project Reach: Piloting a Risk-Tailored Smoking Cessation Intervention for Lung Screening
MINI01.18: Integration of Tobacco Cessation in a Lung Cancer Screening Program
MINI01.19: Cost Analysis of Pemetrexed-Platinum with Maintenance vs. Paclitaxel-Carboplatin-Bevacizumab with Maintenance in Patients with Lung Cancer
MINI01.20: Interim Quality of Life (QoL) Results from ABOUND.sqm: nab -Paclitaxel/Carboplatin Induction Therapy in Squamous (SCC) NSCLC
PS01.01: Simulation in the Management of EGFR-Mutated Advanced NSCLC: Seeing Beyond Age
PS01.02: Thoracic Oncology Clinical Trial Eligibility Criteria: Ongoing Increase in Recent Years
PS01.03: Referral Practices of Medical Oncologists to Palliative Care for Patients with Metastatic Non–Small Cell Lung Cancer (NSCLC)
PS01.04: A Phase II Study of Etirinotecan Pegol (NKTR-102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer
PS01.05: Early and Persistent Oligoclonal T Cell Expansion Correlates with Durable Response to Anti-PD1 Therapy in NSCLC
PS01.06: Tumor Heterogeneity in Lesion Specific Response Creates ROS1 Fusion Mediating Resistance to Gefitinib in EGFR 19 Deletion Lung Adenocarcinoma
PS01.07: Geographical Distribution of Lung Cancer Mortality Worldwide
PS01.08: ABOUND.PS2 Interim Safety Results: nab -Paclitaxel/Carboplatin Followed by nab -Paclitaxel in NSCLC Patients with ECOG PS of 2
PS01.10: Medically Underserved and Geographically Remote Individuals may be Underrepresented in Current Lung Cancer Screening Programs
PS01.11: Comparison of Initial (T0) Screens in UI Health's Minority-Based Lung Cancer Screening Program to that of the National Lung Screening Trial (NLST)
PS01.12: C11-Choline Positron Emission Tomography and the Detection of Primary Lung Cancers
PS01.13: Transbronchial Lung Biopsy on Mechanical Ventilation: Is It Safe To Do?
PS01.14: Diagnostic Yield in Patients Undergoing Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: A Single Center Experience
PS01.15: Outcomes after the Decision to Biopsy: Results from a Nurse Practitioner Run Multidisciplinary Lung Cancer Screening Program
PS01.16: Shortening Time from Diagnosis to Treatment in NSCLC: Are Blood-Based Biopsies the Answer?
PS01.17: Community-Based Low-Dose Computed Tomography (LDCT) Lung Cancer Screening in the US Histoplasmosis Belt: One Year Followup
PS01.18: The Characteristics of Active Pulmonary Tuberculosis in Lung Cancer Patients
PS01.19: Bilateral Endobronchial Typical Carcinoid with Bronchoscopic Therapy: A Retrospective Evaluation
PS01.20: Immune Checkpoints Expression in Small Cell Lung Cancer Lines
PS01.21: Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials
PS01.22: Novel 3-Dimensional Preclinical Models
PS01.23: Epidemiology of Neuroendocrine Tumors (NET) of the Lung in the US: Analysis of 2 Large Insurance Claims Databases
PS01.24: Clinical Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma Characterized by Next-Generation Sequencing
PS01.25: Large Cell Neuroendocrine Carcinoma of the Lung: Prognostic Factors of Survival and Recurrence After R0 Surgical Resection
PS01.26: Prognostic Value of the New WHO Thymoma Classification: Single Institution Cross Validation Study
PS01.27: A Comparison Between Clinically Apparent Gastrointestinal Metastasis of a Primary Lung Carcinoma and the Incidence in Post-Mortem Studies
PS01.28: Epithelial Mesenchymal Transition in TKI Resistant NSCLC with T790M Mutation
PS01.29: The EGFR-mTOR Signaling Axis: a Prognostic Biomarker in Non–Small Cell Lung Carcinoma at the Time of Diagnosis
PS01.30: Domain-Specific c-Met Measurement by Quantitative Immunofluorescence and Mass Spectrometry in Non–Small Cell Lung Cancer
PS01.31: A Reagent-Free, High Resolution Lung Cancer Diagnostic Method Based on Phenotypic Infrared Spectral Imaging
PS01.32: High Throughput Screening of Small Molecule Inhibitors for Nuclear Receptor Subfamily 4 Group A Member 2 (NR4A2) in Human Cancers
PS01.33: Change in microRNA Profile in Lung Cancer Cell Treated with Chemotherapy Cisplatin (C), Pemetrexed (P) or PC with Bevacizumab (B)
PS01.34: Differential Modulation of Glutathione Metabolism in Adeno and Squamous NSCLC by 2HF
PS01.35: Assessing Combretestatin A-4-Phosphate with Multispectral Optoacoustic Tomography as a Treatment for H1299 Lung Cancer
PS01.36: Blood-Based Mutation Testing in Non–Small Cell Lung Carcinoma Patients Supports Individualized and Optimal Treatment
PS01.37: Comparison Between Sanger Sequencing and ARMS qPCR Method for EGFR Gene Mutation Detection of Non–Small Cell Lung Cancer
PS01.38: Patient with a Typical Carcinoid Initially Diagnosed as High-Grade Neuroendocrine Carcinoma
PS01.39: Reach and Adoption of a Surgical Intervention to Improve Pathologic Nodal Staging Across Healthcare Systems within the US Mid-South
PS01.40: Artificial Intelligence, System Analysis and Simulation Modeling in Optimization of Management for Lung Cancer Patients
PS01.41: A Novel Blood Marker of Tumor Prognosis in a Large Cohort of Esophageal Squamous Cell Carcinoma Patients: The Fibrinogen/Albumin Ratio
PS01.42: Predictors of Incomplete Esophageal Cancer Resection: Questionable Role of Preoperative Therapy
PS01.43: Clinically Occult N2 Non–Small Cell Lung Cancer: Timing of Chemotherapy does not affect the Oncologic Outcomes.
PS01.44: 1,000 Video-Assisted Thoracoscopic Lobectomies: A Single institution’s Experience
PS01.45: Intraoperative Blood Loss is an Independent Predictor of Poor Disease Free Survival for Patients Undergoing VATS Lobectomy for Lung Cancer
PS01.46: Robotic Thymectomy: Early Stage Thymoma and Non-Tumor Benign Lesions has Comparable Perioperative Outcomes
PS01.47: PET Volumetric Prognostic Index may be the Most Significant Survival Factor in Non–Small Cell Lung Cancer Treated with Chemoradiation
PS01.48: Radiation Induced Changes of Indoleamine 2, 3-dioxygenase Activities Predict Overall Survival in Patients with Non–Small Cell Lung Cancer
PS01.49: Discrete and Limited Extent of N2 Nodes Associated with Better Outcome of Chemoradiotherapy: Effect of Pretreatment Pathological Diagnoses of N2
PS01.50: Respiratory-Gated Stereotactic Body Radiation Therapy for Stage I Non–Small Cell Lung Cancer: A Retrospective Review
PS01.51: The Impact of PET Staging and Molecular Profiling on the Radiotherapy Outcomes of Primary Lung Adenocarcinoma
PS01.52: New Chemotherapy Regimen: Does it Really Work for Esophageal Cancer Adenocarcinoma?
PS01.53: First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
PS01.54: Evaluation of Novel Blood-Based Biomarkers with Atezolizumab Monotherapy in 1L Advanced or Metastatic NSCLC (B-F1RST)
PS01.55: IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC
PS01.56: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1–Selected Chemotherapy-Naive NSCLC Patients
PS01.57: IMpower133: a Phase I/III Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive-Stage SCLC
PS01.58: A Phase 3 Trial of Nivolumab, Nivolumab Plus Ipilimumab, or Placebo Maintenance for Extensive-Stage SCLC After First-Line Chemotherapy
PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC
PS01.60: Ph Ib/II, Trial of INC280 ± Erlotinib vs Platinum + Pemetrexed in Adult pts with EGFR-Mutated, cMET amplified, EGFR TKI Resistant, Advanced NSCLC
PS01.61: Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now (REVOLUTION): Registry Study in Progress
PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study
PS01.63: Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non–Small Cell Lung Cancer (NSCLC)
PS01.64: Effect of Anti-PD1 Therapy on the Incidence of Thromboembolic Events in Lung Cancer
PS01.65: EGFR Exon 19 Deletion Mutation Patients Obtain Optimal Survival in Icotinib Treated Non–Small Cell Lung Cancer Patient with Brain Metastases
PS01.66: Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC
PS01.67: Case Series of MET Exon 14 Skipping Mutation-Positive Non–Small Cell Lung Cancers and Response to Crizotinib
PS01.68: Heterogeneous Clinical Syndromes Existing Within Patients with Stage IV KRAS Mutant Non–Small Cell Lung Cancer
PS01.69: Indirect Naive Comparison of ALK Inhibitors for ALK+ Non–Small Cell Lung Cancer (NSCLC) Post–Crizotinib Failure
PS01.70: Ceritinib Dosing Patterns and Outcomes of Patients with ALK+ NSCLC in a Real-World Practice in the United States
PS01.71: Patient-Driven Epidemiologic Assessment of ROS1-Fusion Driven Cancers
PS01.72: Payer and Patient Out-of-Pocket Costs: A Projection of the Financial Burden of Non–Small Cell Lung Cancer Care in the United States Through 2040
PS01.73: Have We Shifted the Therapeutic Innovation Frontier? A US Assessment of Advanced Non–Small Cell Lung Cancer (advNSCLC)
PS01.74: Systemic Treatment Sequencing in US Medicare Patients with Extensive Disease (ED)-Small Cell Lung Cancer (SCLC)
PS01.75: Safety Outcomes in Advanced Non–Small Cell Lung Cancer Patients Treated with First-Line Platinum-Based Regimens in the US
PS01.76: Impact of Chemotherapy Intensity on Progression and Survival in Metastatic Non–Small Cell Lung Cancer: A Systematic Review
PS01.77: Risk-Stratification for Second Primary Lung Cancer
PS01.78: Evaluation of Hyponatraemia in Lung Cancer Patients: A UK Teaching Hospital Experience
PS01.79: Epidemiology and Characteristics of US Veterans with NSCLC Using US Veterans Affairs (VA) Database
PS01.80: Genome-Wide Screen of DNA Methylation Changes Reveals GABBR2 as a Novel Potential Target for EGFR 19 Deletion Adenocarcinoma with Erlotinib